[Predictive Molecular Diagnostics in Breast Cancer : What Are the Requirements for Pathology Today and in the Future?]

Overview

Journal Pathologie (Heidelb)

Specialty Pathology

Date 2022 Aug 15

PMID 35969265

Authors

Peter J Wild

Carsten Denkert

C Jackisch

Affiliations

Soon will be listed here.

Abstract

With an increasing number of targeted therapy options for the treatment of solid tumors, the demands on predictive molecular diagnostics for pathology are growing. In breast cancer the need to determine genomic predictive markers for available targeted therapies has so far been manageable (detection of PIK3CA mutations in endocrine pretreated luminal tumors and the search for NTRK fusions indicated only in secretory breast cancer). At the latest in cases of nonresponse to first-line or second-line standard treatment, more comprehensive diagnostics using next generation sequencing (NGS) panel diagnostics makes sense. This should be suitable for clarifying resistance mechanisms, e.g. against endocrine therapy or cyclin-dependent kinase 4/cyclin-dependent kinase 6 (CDK4/6) inhibitors and to identify indications for therapies currently in development. The interpretation should be carried out in a quality assured manner in accordance with international standards and the interdisciplinary tumor board should make a transparent and standardized report available in a timely manner.

Citing Articles

HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice.

Albert V, Bruss C, Tumen D, Piendl G, Weber F, Dahl E Int J Mol Sci. 2024; 25(13).

PMID: 39000582 PMC: 11242770. DOI: 10.3390/ijms25137475.

References

Pedini P, Graiet H, Laget L, Filosa L, Chatron J, Cherouat N . Qualitative and quantitative comparison of cell-free DNA and cell-free fetal DNA isolation by four (semi-)automated extraction methods: impact in two clinical applications: chimerism quantification and noninvasive prenatal diagnosis. J Transl Med. 2021; 19(1):15. PMC: 7788686. DOI: 10.1186/s12967-020-02671-8. View

Hodgson D, Lai Z, Dearden S, Barrett J, Harrington E, Timms K . Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Ann Oncol. 2021; 32(12):1582-1589. DOI: 10.1016/j.annonc.2021.08.2154. View

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

Fribbens C, OLeary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M . Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol. 2016; 34(25):2961-8. DOI: 10.1200/JCO.2016.67.3061. View

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N . A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018; 29(9):1895-1902. PMC: 6158764. DOI: 10.1093/annonc/mdy263. View

Angus L, Smid M, Wilting S, van Riet J, Van Hoeck A, Nguyen L . The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019; 51(10):1450-1458. PMC: 6858873. DOI: 10.1038/s41588-019-0507-7. View

Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M . TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med. 2021; 10(23):8581-8594. PMC: 8633262. DOI: 10.1002/cam4.4376. View

Li M, Datto M, Duncavage E, Kulkarni S, Lindeman N, Roy S . Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2016; 19(1):4-23. PMC: 5707196. DOI: 10.1016/j.jmoldx.2016.10.002. View

10.

Marchio C, Scaltriti M, Ladanyi M, Iafrate A, Bibeau F, Dietel M . ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019; 30(9):1417-1427. DOI: 10.1093/annonc/mdz204. View

11.

OLeary B, Finn R, Turner N . Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016; 13(7):417-30. DOI: 10.1038/nrclinonc.2016.26. View

12.

Cortes-Ciriano I, Lee S, Park W, Kim T, Park P . A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017; 8:15180. PMC: 5467167. DOI: 10.1038/ncomms15180. View

13.

Winter C, Nilsson M, Olsson E, George A, Chen Y, Kvist A . Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016; 27(8):1532-8. PMC: 4959927. DOI: 10.1093/annonc/mdw209. View

14.

Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, Vasan N . The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018; 34(3):427-438.e6. PMC: 6327853. DOI: 10.1016/j.ccell.2018.08.008. View

15.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

16.

Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale S . AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?. Front Pharmacol. 2021; 12:662232. PMC: 8118639. DOI: 10.3389/fphar.2021.662232. View

17.

Deniziaut G, Tille J, Bidard F, Vacher S, Schnitzler A, Chemlali W . ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. Oncotarget. 2016; 7(45):73337-73346. PMC: 5341983. DOI: 10.18632/oncotarget.11819. View

18.

Campbell I, Russell S, Choong D, Montgomery K, Ciavarella M, Hooi C . Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64(21):7678-81. DOI: 10.1158/0008-5472.CAN-04-2933. View

19.

Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B . Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol. 2021; 14(1):157. PMC: 8480024. DOI: 10.1186/s13045-021-01169-0. View

20.

Godsey J, Silvestro A, Barrett J, Bramlett K, Chudova D, Deras I . Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC's Analytical Variables Working Group. Clin Chem. 2020; 66(9):1156-1166. PMC: 7462123. DOI: 10.1093/clinchem/hvaa164. View